All In Biotech

Drug Trial Radar · NCT07708727

Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment

An Operationally Seamless Phase 2/3 Randomized, Open-label, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 in Combination With Lenacapavir Versus Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Treatment-Naive People With HIV-1

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 700 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

700

Planned (sponsor's estimate)

Start

Jul 29, 2026

Primary completion

Oct 2030

Study completion Apr 2033

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Jul 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will have two portions: Phase 2 and Phase 3. Phase 2 will further have 2 parts: Part A and Part B. The goal of Phase 2, Part A is to assess the effectiveness of study drugs GS-3242 plus Lenacapavir (LEN) versus Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)), in people with HIV-1 (PWH) who are new to treatment. This will be done in Treatment Groups 1, 2 and 3 at Week 35. The goal of Phase 2, Part B is to compare the effectiveness of study drugs, GS-3242 and LEN versus B/F/TAF in Groups 4 and 3 at Week 26. The goal of Phase 3 is to assess the long-term effectiveness of study drug GS-3242 and LEN versus B/F/TAF, at Week 52. The primary objectives of this study are: Phase 2, Part A: To evaluate the efficacy of intramuscular (IM) GS-3242 plus IM LEN versus B/F/TAF in treatment-naive people with HIV-1 (PWH) in Treatment Groups 1, 2, and 3 at Week 35. Phase 2, Part B: To evaluate the efficacy of IM GS-3242 plus IM LEN versus B/F/TAF in treatment-naive PWH in Treatment Groups 4 and 3 at Week 26. Phase 3: To evaluate the efficacy of IM GS-3242 plus IM LEN versus B/F/TAF in treatment-naive PWH at Week 52.

Conditions

  • HIV-1-infection

Interventions

  • GS-3242 TabletDrug

    Administered orally

  • GS-3242 InjectionDrug

    Administered intramuscularly (IM)

  • Lenacapavir TabletDrug

    Administered orally

  • Lenacapavir InjectionDrug

    Administered IM

  • B/F/TAFDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2: Part A: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 35 as Determined by the United States (US) Food and Drug Administration (FDA) Snapshot AlgorithmTime frame: Week 35
  2. Phase 2: Part B: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 26 as Determined by the US FDA Snapshot AlgorithmTime frame: Week 26
  3. Phase 3: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA Snapshot AlgorithmTime frame: Week 52

Locations

21 sites in 5 countries. Site status is shown where the registry gives one.

  • Lundquist Inst Biomedical Innovation Harbor-UCLA

    Torrance, California · Recruiting

  • Yale University; School of Medicine; AIDS Program

    New Haven, Connecticut · Recruiting

  • Midway Immunology and Research Center

    Ft. Pierce, Florida · Recruiting

  • Floridian Clinical Research, LLC

    Miami Lakes, Florida · Recruiting

  • Orlando Immunology Center, PA

    Orlando, Florida · Recruiting

  • Triple O Research Institute, P.A.

    West Palm Beach, Florida · Recruiting

  • Emory University Hospital Midtown Infectious Disease Clinic

    Atlanta, Georgia · Recruiting

  • Metro Infectious Disease Consultants, P.L.L.C

    Decatur, Georgia · Recruiting

  • KC care Health Center

    Kansas City, Missouri · Recruiting

  • Saint Michael's Medical Center

    Newark, New Jersey · Recruiting

  • St Hope Foundation, Inc,

    Bellaire, Texas · Recruiting

  • Prism Health North Texas

    Dallas, Texas · Recruiting

  • North Texas Infectious Diseases Consultants, PA

    Dallas, Texas · Recruiting

  • Texas Centers for Infectious Disease Associates

    Fort Worth, Texas · Recruiting

  • MultiCare Health System - Deaconess Medical Office Building 2

    Spokane, Washington · Recruiting

  • McGill University Health Centre

    Decarie Montreal, Canada · Recruiting

  • CHU de Québec-Université Laval

    Québec, Canada · Recruiting

  • ICH Study Center GmbH & Co. KG

    Hamburg, Germany · Not yet recruiting

  • Proyecto ACTU

    Rio Piedras, PR, Puerto Rico · Recruiting

  • HOPE Clinical Research

    San Juan, PR, Puerto Rico · Recruiting

  • Hospital Universitario Virgen de las Nieves

    Granada, Spain · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.